Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire

Antiviral Therapy

Volumn 10, Issue 5, 2005, Pages 615-624

  Moh, Raoul ^a   Danel, Christine ^a   Sorho, Souleymane ^a   Sauvageot, Delphine ^a   Anzian, Amani ^b   Minga, Albert ^c   Ba Gomis, Olivier ^d   Kanga, Constance ^e   Inwoley, André ^e   Gabillard, Delphine ^f   Bissagnene, Emmanuel ^e   Salamon, Roger ^a,f   Anglaret, Xavier ^a,f  

^a Programme PAC CI   (Côte d’Ivoire)

^b CePReF   (Côte d’Ivoire)

^c Ctr Natl de Transfusion Sanguine   (Côte d’Ivoire)

^d CIRBA   (Côte d’Ivoire)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD CELL COUNT; BLOOD PLATELETS; COHORT STUDIES; COTE D'IVOIRE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEUTROPENIA; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZIDOVUDINE;

EID: 24044545281     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. UN AIDS/WHO. Provisional WHO/UNAIDS Secretariat Recommendations on the Use of Cotrimoxazole Prophylaxis in Adults and Children Living with HIV/AIDS in Africa. 2000. http://www.unaids.org/html/pub/publications/irc-pub04/ recommendation_en_pdf/recommendation_en_pdf_1.jpg
2. Huët C, Anglaret X, Toure S, Combe P, Gourvellec G, Koffi J, N'Dri-Yoman T, Dabis F & Salamon R. Incidence and risk factors of neutropenia in HIV-1 infected patients under cotrimoxazole prophylaxis. 13th International AIDS Conference. 9-14 July 2000, Durban, South Africa. Abstract TuPeC3393.
3. Moore RD, Fortgang I, Keruly J & Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. American Journal of Medicine 1996; 101:34-40.
4. WHO. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach; 2003 revision, http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf
5. Moyle G, Sawyer W, Law M, Amin J & Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clinical Therapeutics 2004; 26:92-97.
6. Moore DA, Benepal T, Portsmouth S, Gill J & Gazzard BG. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clinical Infectious Diseases 2001; 32:469-475.
7. Danel C, Moh R, Sorho S, Anzian A, Abo Y, Chenal H, Kanga C, Eholié S, Sauvageot D, Gabillard D, Rouet F, Bissagnene E, Anglaret X & Salamon R. Progress report on a structured treatment interruption trial: Trivacan ANRS 1269 trial, Abidjan, Côte d'Ivoire. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract WeOrB1284.
8. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati P, Dabis F & Rouzioux C for the ANRS Côte d'Ivoire PAC-CI Program. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. Journal of Clinical Microbiology 2005; 43:2709-2717.
9. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, Kane CT, Delaporte E, Sow PS, Faye MA, Gueye M, Peytavin G, Dalban C, Girard PM & Ndoye I. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003; 17:1017-1022.
10. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liegeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngole E & Delaporte E. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
11. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, Diakite N, Daudie A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T & Salamon R. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antiviral Therapy 2003; 8:385-393.
12. Laurent C, Diakhaté N, Ngom Gueye N, Touré M, Sow P, Faye M, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I & Delaporte E. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
13. Jack C, Lalloo U, Karim QA, Karim SA, El-Sadr W, Cassol S & Friedland G. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes 2004; 36:929-934.
14. Weidle P, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, Samb B & Lackritz E. Assessement of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
15. Badri M, Wilson D & Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
16. Livesley N & Morris C. Antiretroviral therapy in a primary care clinic in rural South Africa. AIDS 2003; 17:2005-2006.
17. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F & Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-1168.
18. Orrell C, Bangsberg DR, Badri M & Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369-1375.
19. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N & Goemaere E. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
20. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T & Salamon R. Early chemoprophylaxis with trimethoprim- sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468.
21. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM & Greenberg AE. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-1475.
22. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W & Quick R. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434.
23. Maynart M, Lievre L, Sow P, Kony S, Gueye N, Bassene E, Metro A, Ndoye I, Ba D, Coulaud J & Costagliola D. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. Journal of Acquired Immune Deficiency Syndromes 2001; 26:130-136.
24. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Reviews 2002; 4:13-20.
25. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D & Hirsch MS. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 1987; 317:192-197.
26. Gelmon K, Montaner JS, Fanning M, Smith JR, Falutz J, Tsoukas C, Gill J, Wells G, O'Shaughnessy M, Wainberg M & Reudy J. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989; 3:555-561.
27. Rubin RH & Swartz MN. Trimethoprim-sulfamethoxazole. New England Journal of Medicine 1980; 303:426-432.
28. Hughes WT, LaFon SW, Scott JD & Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. Journal of Infectious Diseases 1995; 171:1295-1301.
29. Sullivan PS, Hanson DL, Chu SY, Jones JL & Ward JW Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91:301-308.
30. Freund YR, Dousman L, MacGregor JT & Mohagheghpour N. Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses. Toxicological Sciences 2000; 55:335-342.
31. Reisler RB, Han C, Burman WJ, Tedaldi EM & Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. Journal of Acquired Immune Deficiency Syndromes 2003; 34:379-386.
32. Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH & Smaldone L. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Annals of Internal Medicine 1994; 120:360-368.
33. Shaper AG & Lewis P. Genetic neutropenia in people of African origin. Lancet 1971; 2:1021-1023.
34. Rezvani K, Flanagan AM, Sarma U, Constantinovici N & Bain BJ. Investigation of ethnic neutropenia by assessment of bone marrow colony-forming cells. Acta Haematologica 2001; 105:32-37.
35. Jacobson MA, Gundacker H, Hughes M, Fischl M & Volberding P. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis or two multicenter placebo-controlled trials. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1996; 11:45-52.
36. Chatton JAM, Chave JP, Steinhauslin F, Roch-Ramel F, Glauser M & Biollaz J. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. British Journal of Clinical Pharmacology 1992; 34:551-554.
37. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B & Jacob P 3rd. Ethnic differences in N-glucuronidation of nicotine and cotinine. Journal of Pharmacology & Experimental Therapeutics 1999; 291:1196-1203.
38. Meynard JL, Guiguet M, Arsac S, Frottier J & Meyohas MC. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. AIDS 1997; 11:995-998.
39. Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, Santoscoy M & Nieto-Cisneros L. Lamivudine-induced pure red cell aplasia. American Journal of Hematology 2000; 65:189-191.
40. Pluda J, Cooley T, Montaner J, Shay L, Reinhalter N, Warthan S, Ruedy J, Hirst H, Vicary C, Quinn J, Yuen GJ, Wainber MA, Rubin M & Yarchoan R. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases 1995; 171:1438-1447.
41. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK & Hussey EK. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clinical Pharmacology & Therapeutics 1996; 59:550-558.
42. Reinke CM, Thomas JK & Graves AH. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. Journal of Pharmacy Technology 1996; 11:256-362; quiz 93-95.
43. Zon LI, Arkin C & Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). British Journal of Haematology 1987; 66:251-256.
44. Shaunak S & Bartlett JA. Zidovudine-induced neutropenia: are we too cautious? Lancet 1989; 2:91-92.
45. Moore RD & Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 29:54-57.